The U.S. Food and Drug Administration (FDA) has revised the label for Metformin Hydrochloride, effective 2026-07-28, to include a prominent boxed warning concerning the risk of lactic acidosis. This severe adverse event, identified through postmarketing cases, has led to serious outcomes including death, hypothermia, hypotension, and resistant bradyarrhythmias. The warning emphasizes that the onset of metformin-associated lactic acidosis is often subtle.
Background
Metformin Hydrochloride is a cornerstone medication for the management of type 2 diabetes, often prescribed as a first-line therapy. It is available as a standalone product and in combination formulations, such as with canagliflozin in drugs like Invokamet and Invokamet XR. The drug works by decreasing glucose production in the liver, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. While generally well-tolerated, metformin has a known association with lactic acidosis, a rare but potentially fatal metabolic complication. This new boxed warning serves to highlight and reinforce this critical safety information for prescribers and patients.
What this means
The addition of a boxed warning to the Metformin Hydrochloride label signifies a heightened emphasis on the risk of lactic acidosis. For clinicians, this means an increased imperative to carefully assess patient risk factors before initiating or continuing metformin therapy, including renal function, concomitant medications, and conditions predisposing to hypoxia or dehydration. Early recognition of symptoms, which can be subtle, is crucial for timely intervention. Patient advocates and patients themselves should be fully informed about the signs and symptoms of lactic acidosis, such as malaise, myalgia, respiratory distress, and abdominal pain, to seek immediate medical attention if they occur. This label change reinforces the importance of vigilant monitoring and patient education to mitigate the risks associated with this essential diabetes medication.
Source
This information is based on an FDA label revision for Metformin Hydrochloride, effective 2026-07-28. The details are available on the dailymed.nlm.nih.gov website.